EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Plasma Volume Status Predicting Clinical Outcomes in Patients Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair

Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta und 19 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15295 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Ai Kagase und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nagoya Heart Center, Nagoya, Japan. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Mitral Valve, Registries, Cardiac Catheterization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Edwards Lifesciences, Medtronic, Boston Scientific.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients. Methods and results Data from 3763 patients who underwent M-TEER were analysed from a Japanese multicentre registry. Patients were classified into functional MR (FMR) and degenerative MR (DMR) according to MR aetiology, and the median PVS values for each were calculated (FMR 12.7, DMR 14.4). The median value was used as the cut-off, stratifying the cohort into a high PVS group (n = 1882) and a low PVS group (n = 1881). All-cause mortality, cardiovascular death, and heart failure (HF) hospitalization between these two groups were compared up to 3 years in the overall, FMR, and DMR populations. The cumulative incidence rates of all-cause mortality, cardiovascular death, and HF hospitalization were higher in the high PVS group than in the low PVS group (47.0% vs. 22.2%, P < 0.001, 31.6% vs. 13.6%, P < 0.001, and 35.9% vs. 24.7%, P < 0.001, respectively). Similar trends in terms of all-cause mortality, cardiovascular death, and HF hospitalization were observed in the FMR and DMR cohorts (all P < 0.05). In the multivariate Cox regression analysis, the high PVS compared with the low PVS group was independently associated with the increased risk of all-cause death (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01–1.03; P < 0.001), cardiovascular death (HR, 1.02; 95% CI, 1.01–1.03, P < 0.001) and HF hospitalization (HR, 1.02; 95% CI, 1.01–1.02, P < 0.001). An independent association between a high PVS and all-cause death, cardiovascular death, and HF hospitalization was also found in FMR and DMR sub-groups (all P < 0.05) while reducing MR severity to moderate or less after M-TEER was associated with improved outcomes in both the high and low PVS groups.

Conclusions

Preoperative PVS is a strong independent prognostic marker in patients undergoing M-TEER, correlating with increased risk of mortality and HF hospitalization. PVS may provide valuable clinical insights for patient stratification and management strategies in M-TEER patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyMitral ValveRegistriesCardiac CatheterizationPlasma VolumeHeart Valve Prosthesis ImplantationHumansMaleFemaleJapanAgedPrognosisRetrospective StudiesFollow-Up StudiesAged, 80 and overSurvival RateTreatment OutcomeEchocardiography, Transesophageal

Stichwörter der Autor:innen

Heart failureMitral regurgitationPlasma volume statusTranscatheter edge‐to‐edge mitral valve repair

Autor:innen und Institutionen

  • Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.
  • Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.
  • Department of Cardiology, Gifu Heart Center, Gifu, Japan.
  • Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
  • Division of Cardiovascular Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
  • Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.

Förderung

  • Edwards Lifesciences
  • Medtronic
  • Boston Scientific
  • Abbott Medical
  • Daiichi-Sankyo Company
  • Boston Scientific Corporation
  • Abbott Medical Optics

Zitieren

APA

Kagase, A., Yamamoto, M., Tokuda, T., Kawahata, R., Nishio, H., Shimura, T., Yamaguchi, R., Sago, M., Izumi, Y., Saji, M., Asami, M., Enta, Y., Nakashima, M., Shirai, S., Izumo, M., Mizuno, S., Watanabe, Y., Amaki, M., Kodama, K., …, & OCEAN‐Mitral Investigators (2025). Plasma Volume Status Predicting Clinical Outcomes in Patients Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair. ESC Heart Failure. https://doi.org/10.1002/ehf2.15295

Vancouver

Kagase A, Yamamoto M, Tokuda T, Kawahata R, Nishio H, Shimura T, et al. Plasma Volume Status Predicting Clinical Outcomes in Patients Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair. ESC Heart Failure. 2025. doi:10.1002/ehf2.15295

BibTeX
@article{Kagase2025,
  author = {Kagase, Ai and Yamamoto, Masanori and Tokuda, Takahiro and Kawahata, Ryotaku and Nishio, Hiroto and Shimura, Tetsuro and Yamaguchi, Ryo and Sago, Mitsuru and Izumi, Yuki and Saji, Mike and Asami, Masahiko and Enta, Yusuke and Nakashima, Masaki and Shirai, Shinichi and Izumo, Masaki and Mizuno, Shingo and Watanabe, Yusuke and Amaki, Makoto and Kodama, Kazuhisa and Yamaguchi, Junichi and Naganuma, Toru and Bouta, Hiroki and Ohno, Yohei and Yamawaki, Masahiro and Ueno, Hiroshi and Mizutani, Kazuki and Hachinohe, Daisuke and Otsuka, Toshiaki and Kubo, Shunsuke and Hayashida, Kentaro and OCEAN‐Mitral Investigators, OCEAN‐Mitral Investigators},
  title = {Plasma Volume Status Predicting Clinical Outcomes in Patients Undergoing Transcatheter Edge-To-Edge Mitral Valve Repair},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15295}
}
Kostenlos starten →